Explore 3 Stock Ideas & Industry Insights Download Free Report

News

What Daly Meant by Consumers Running Out of Gas

● Inflation remains the Fed's priority.

Nitish Kishor | 16 November 2026

Why This Week's Hot CPI and PPI Combo Rattled Rate-Sensitive Stocks

Key Highlights● Back-to-back hot CPI and PPI reports rattled rate-sensitive stocks.● Expectations for another Fed hike were cemented.● Bond yields rose.● Defensive names held up.The week delivered twoInflationreports that pointed the same way. On Tuesday, November 10, 2026, the OctoberConsumer Price Indexcame in hotter …

Nitish Kishor | 16 November 2026

Why Capri Holdings (NYSE:CPRI) Climbed on the NYSE Composite Days After Capri Named a New CEO

● The fashion group owns Michael Kors and Jimmy Choo.

Nitish Kishor | 16 November 2026

Why Circle (NYSE:CRCL) Slid on the NYSE Composite as Bitcoin Hit a Three-Month Low

Key Highlights● Circle slid on Friday.● Bitcoin fell below $70,000 for the first time in nearly three months.● Crypto-linked stocks moved lower.● Nvidia reports quarterly results on Tuesday, November 17.Circle (NYSE:CRCL) slid on Friday, November 13, 2026, and was trending among the decliners on …

Nitish Kishor | 16 November 2026

Balyasny Discloses 4.34% Stake in Crescent Biopharma

Balyasny Asset Management L.P. and related reporting persons filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,611,958 shares of common stock in Crescent Biopharma, Inc. as of September 30, 2026.

Anjali Anand | 16 November 2026

Balyasny Discloses 9.99% Stake in Cellectar Biosciences

Balyasny Asset Management L.P. and related entities filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 944,265 shares of Cellectar Biosciences, Inc. common stock, representing approximately 9.99% of the class as of September 30, 2026.

Anjali Anand | 16 November 2026

Balyasny Reports 7.36% Stake in Opus Genetics

Balyasny Asset Management L.P. and related reporting persons filed Amendment No. 3 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,120,982 shares of Opus Genetics Inc. common stock as of September 30, 2026.

Anjali Anand | 16 November 2026

Balyasny Discloses 1.26% Stake in Korsana Biosciences

Balyasny Asset Management L.P. and related reporting persons filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 572,533 shares of common stock in Korsana Biosciences, Inc. as of September 30, 2026.

Vinay Lochav | 16 November 2026

Feng Yang Reports 8.4% Stake in Intchains Group

Yang Feng 888 Capital Limited and its sole owner Feng Yang filed Amendment No. 1 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,400,000 Class A ordinary shares of Intchains Group Limited as of September 30, 2026.

Vinay Lochav | 16 November 2026
Support

Hi! How can we help you today?

Loading…